Integral Diagnostics

Integral Diagnostics FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Integral Diagnostics (IDX.AX) as of Sep 21, 2026 is 207.90 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 299.87 % — a change of -30.67% (lower).

FCF Conversion

207.90 %

YoY

-30.67%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Integral Diagnostics is 2026 207.90 % . FCF Conversion Rate (FCF/EBITDA) of Integral Diagnostics was 2025 299.87 % . It decreases by -30.67% lower compared to the previous year.

The Integral Diagnostics FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2019
72.70 AUD
Jan 1, 2020
123.19 AUD
Jan 1, 2021
157.67 AUD
Jan 1, 2022
63.89 AUD
Jan 1, 2023
109.52 AUD
Jan 1, 2024
-69.66 AUD
Jan 1, 2025
299.87 AUD
Jan 1, 2026
207.90 AUD
The Integral Diagnostics FCF Conversion history
YEARFCF ConversionYoY
207.90 %-30.67%
299.87 %-530.50%
-69.66 %-163.60%
109.52 %+71.41%
63.89 %-59.48%
157.67 %+27.99%
123.19 %+69.45%
72.70 %-26.62%
99.07 %+38.41%
71.58 %+19.29%
60.00 %-82.19%
336.84 %+562.19%
50.87 %
Access this data via the Eulerpool API

Integral Diagnostics Stock analysis

What does Integral Diagnostics do? Integral Diagnostics Ltd is an Australian company that has been providing medical imaging services for over 25 years. The company was founded in 1994 by Dr. Ian Kadish and a team of radiologists in Perth, Western Australia, offering radiology services to local clinics and hospitals. Over the years, Integral Diagnostics has expanded its services to provide imaging services nationwide. The business model of Integral Diagnostics is to deliver medical imaging to enable doctors and their patients to have a fast and accurate diagnosis. The company offers imaging services for a variety of medical specialties, including radiology, cardiology, obstetrics and gynecology, and neurology. They operate over 49 locations in Australia, many of which are in rural areas where access to medical care may be limited. Integral Diagnostics offers a wide range of products based on medical imaging. These include X-rays, mammography, ultrasound, CT scans, MRI scans, PET scans, and bone density scans. The company takes pride in being one of the few Australian medical imaging companies to offer a complete range of imaging services. Their services are conducted by qualified radiologists specialized in interpreting medical images. Integral Diagnostics also operates clinics for performing diagnostic and therapeutic procedures such as biopsies, drainages, and injections. These procedures are carried out by highly qualified radiologists to provide patients with faster and more accurate diagnoses. Integral Diagnostics is committed to quality assurance and has a comprehensive quality management system that is annually reviewed by independent auditors. The company is accredited by both the Australian Medical Association and the Australian National Accreditation Scheme (NATA). These accreditations recognize the high standards that Integral Diagnostics sets for delivering medical imaging services. One of Integral Diagnostics' recent activities is their use of artificial intelligence (AI) in image interpretation. The company has partnered with MaxQ AI, a leading provider of AI solutions for medical imaging. Through this partnership, Integral Diagnostics doctors can utilize the latest AI tools to improve their patients' diagnoses. Integral Diagnostics is a strong advocate for social justice and is dedicated to supporting disadvantaged communities in Australia. The company has partnered with nonprofit organizations such as the National Breast Cancer Foundation, The Smith Family, and the Friendship Foundation. Overall, Integral Diagnostics has undergone impressive growth over the past 25 years and is now a leading Australian medical imaging company. With a wide range of imaging services and a strong focus on quality and social responsibility, the company is well-positioned to continue its success in the future. Integral Diagnostics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Integral Diagnostics stock

FCF Conversion Rate (FCF/EBITDA) of Integral Diagnostics is 207.90 % in 2026.

FCF Conversion Rate (FCF/EBITDA) of Integral Diagnostics changed from 299.87 % to 207.90 %, representing a -30.67% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Integral Diagnostics since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Integral Diagnostics with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

Cash Flow — Integral Diagnostics

All Key Metrics — Integral Diagnostics